Biograil™
We're developing breakthrough technology for oral delivery of biologics
We're developing breakthrough technology for oral delivery of biologics
Biograil is a Denmark-based biotechnology startup founded in 2019 with the slogan, "We're developing breakthrough technology for oral delivery of biologics." The company is focused on leveraging its proprietary BIONDD™ technology to transform the market of injectable pharmaceutical products into convenient oral capsules. Their last investment, a Seed Round, took place on 04 October 2022, with Arve Capital being the investor. Biograil aims to make pharmaceuticals more effective and convenient for patients by combining known technologies in innovative and proprietary ways. As they continue to progress through their pre-clinical stage, this venture presents an exciting opportunity for investors looking to support groundbreaking advancements in pharmaceutical delivery technology within the biotechnology and manufacturing industries.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Seed Round | Unknown | 1 |
|
04 Oct 2022 |
| Seed Round | €3.00M | 4 |
|
17 Jan 2020 |
No recent news or press coverage available for Biograil™.
We care about your data, and we'd love to use cookies make your experience better.
